Primary bone lymphoma is a rare condition which represents a low percentage of both the malignant primary bone tumours and the non-Hodgkin extranodal lymphoma. This explains the lack of publications, lines of investigations, and specific diagnostic and treatment protocols. In the following article we will carry out a revision of the existing literature on this rare subject, using as argument a clinical case of left femoral location stage IE treated with CHOP chemotherapy and radiotherapy.
Aim: The prognosis of recurrent glioblastoma (GB) is poor. The median survival after progression to Stupp protocol is 3-6 months. After the implementation of the NeuroCommittee (CNON) in our center, second treatment options have changed life expectancy without reducing the quality of life.Objectives: Show the selection criteria for second-line treatments in GB. Show overall survival (OS) and progression free survival (PFS) for each treatment group. Methods: We selected 18 patients with recurrent GB treated with surgery + radiotherapy + chemotherapy according Stupp protocol, between January 2010 and December 2013. After assessing the results in CNON, we differenciate two groups: Group 1 (n = 8), Patients who underwent surgical re-intervention + Carmustine implant polymers vs Group 2 (n = 10) those who could not benefit from surgery and received bevacizumab + Irinotecan. We analyzed 20 variables in each patient. Results: In the Group 1 median OS was 10 months (CI 95%: 4,762-15.238), and the PFS was 8 months (CI 95% 5,772). In the Group 2 median OS was 35.15 months (CI 95%,) and the FPS was 20 months (CI 95% 0 -40.144 months). In both groups morbidity and toxicity were acceptable and the quality of life was no affected. Conclusions: Since the establishment by the CNON of a protocol for monitoring and second-line treatment in patients with GB, the overall survival has increased significantly. Of the two options presented, it seems more benefit treatment with Avastin + irinotecan and although the sample size is small, we should think in the adoption of more aggressive therapeutic options in the future. Disclosure: All authors have declared no conflicts of interest.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.